Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy
Emrush Rexhaj, Sarah Bär, Rodrigo Soria, et al.
Atherosclerosis (2024) Vol. 392, pp. 117504-117504
Open Access | Times Cited: 9

Showing 9 citing articles:

Endothelial dysfunction: molecular mechanisms and clinical implications
Xia Wang, Ben He
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 22
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Fotios Barkas, Yusuf Ziya Şener, Pelin Golforoush, et al.
Atherosclerosis (2024) Vol. 395, pp. 117579-117579
Closed Access | Times Cited: 12
Lipid-lowering Therapy and Coronary Plaque Regression
Yasushi Ueki, Tadashi Itagaki, Koichiro Kuwahara
Journal of Atherosclerosis and Thrombosis (2024) Vol. 31, Iss. 11, pp. 1479-1495
Open Access | Times Cited: 3
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes
Kyriakos Dimitriadis, Nikolaos Pyrpyris, Panagιotis Iliakis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 17, pp. 5040-5040
Open Access | Times Cited: 3
PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?
Lucia Barbieri, Gabriele Tumminello, Isabella Fichtner, et al.
Current Atherosclerosis Reports (2024) Vol. 26, Iss. 10, pp. 589-602
Open Access | Times Cited: 2
PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
Maram H. Abduljabbar
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1581-1581
Open Access | Times Cited: 1
Rationale for Early Administration of PCSK9 Inhibitors in Acute Coronary Syndrome
Salvatore Giordano, Jessica Ielapi, Nadia Salerno, et al.
Reviews in Cardiovascular Medicine (2024) Vol. 25, Iss. 10
Open Access
Exploring research trends and hotspots on PCSK9 inhibitor studies: a bibliometric and visual analysis spanning 2007 to 2023
Ping Lai, Shuquan Xu, Ziyou Liu, et al.
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access
Assessing the impact of evolocumab on thin-cap fibroatheroma and endothelial function in patients with very high-risk atherosclerotic cardiovascular disease: a study protocol for a randomized controlled trial
Bingyu Gao, Nan Nan, Mingduo Zhang, et al.
Cardiovascular Diagnosis and Therapy (2024) Vol. 14, Iss. 6, pp. 1236-1246
Open Access
Page 1

Scroll to top